BioPharmSignal logoBioPharmSignal

Biotech News

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Candel Therapeutics (CADL)Candel Therapeutics2026-06-25 13:46 ESTEarnings

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.

Open original release

Related news

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics to Present at Upcoming Investor Conferences

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Announces Proposed $100 Million Public Offering

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Announces Pricing of Public Offering

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

View all latest news

Candel Therapeutics

Candel Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CADLCandel Therapeutics2026-06-26 07:27 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

CADLCandel Therapeutics2026-06-26 07:27 EST

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

CADLCandel Therapeutics2026-06-26 07:27 EST

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

CADLCandel Therapeutics2026-06-26 07:27 EST

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-06-26 07:27 EST

Candel Therapeutics to Present at Upcoming Investor Conferences

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States